Special Report - Feb 25, 2021
Issue 7 - Feb 19, 2021
Issue 6 - Feb 12, 2021
  • NCI Director’s Report

    NCI raises paylines, commemorates 50th anniversary of the National Cancer Act of 1971

    Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.

  • Black History Month

    VCU’s Rob Winn reflects on a year of COVID, racial reckoning, and being the sole Black director of an NCI-designated cancer center

    Being Black and running an NCI-designated cancer center at a time of a worldwide pandemic, an ugly election, and a racial reckoning in a Southern town puts you in a position to make profound observations.

  • Come back later: ODAC rejects accelerated approval of neoadjuvant Keytruda in TNBC

    In a unanimous vote, the FDA Oncologic Drugs Advisory Committee recommended against an accelerated approval for Keytruda for patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery.

  • Uğur Şahin: Pfizer-BioNTech mRNA coronavirus vaccine is “fastest vaccine developed and approved in medical history”

    When Uğur Şahin and his wife Özlem Türeci founded their company, BioNTech, in 2008, they set out to explore novel modalities for treating cancer—including messenger ribonucleic acid, a well-understood single-stranded molecule featured in most Biology 101 textbooks.

  • Peter Marks: How FDA crunched COVID-19 vaccine review timelines without compromising safety or efficacy

    Faced with a pandemic that kills thousands of Americans each day, FDA leadership had to get therapeutics and vaccines for SARS-CoV-2 onto the market with unprecedented speed without sacrificing standards.

  • In Brief

    • Anne Chiang named deputy chief medical officer and chief integration officer at Smilow Cancer Hospital
    • Sachin Apte named chief clinical officer of Huntsman Cancer Institute
    • Alan Tackett named deputy director of UAMS Winthrop P. Rockefeller Cancer Institute
    • Sybil R. Green named first diversity and inclusion officer of ASCO
    • Patrick Delaney named executive director of NCCN Foundation
    • City of Hope receives $100M donation from Arthur Riggs
    • MSK receives $7M donation, establishes newly endowed chair and fellowships for health equity and diversity
    • Yale Cancer Center and Smilow Cancer Hospital receives $750,000 grant to address cancer health inequality
    • Biden’s former Cancer Moonshot Blue Ribbon panel members, oncology leaders pen letter supporting Janet Woodcock for FDA commissioner
  • Funding Opportunities

    DOD ovarian cancer research funding opportunity for FY21

    The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.

  • TCCL Logo

  • Clinical Roundup

    • ASCO, Friends of Cancer Research recommend broadening eligibility criteria in cancer clinical trials
    • CRISPR tech targets human genome’s complex code
  • Drugs & Targets

    • Ukoniq receives FDA accelerated approval for marginal zone lymphoma and follicular lymphoma
    • Breyanzi receives FDA approval for adults with relapsed or refractory large-B-cell lymphoma
    • Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma
    • MD Anderson, Mirati Therapeutics collaborate on KRAS and solid tumor research
    • Inrebic received European Commission approval for myelofibrosis